The Difference in Negative Scale Score Measured with Positive and Negative Syndrome Scale in Schizophrenic Male Patient Treated with Risperidone in Addition to Vitamin E and Treated with Risperidone Alone at Prof. Dr. M. Ildrem Mental Hospital Medan
DOI:
https://doi.org/10.3889/oamjms.2021.6341Keywords:
Schizophrenia, Vitamin E, Negative scale PANSS scoreAbstract
OBJECTIVES: The objectives of the study were to investigate the difference in negative scale score in schizophrenic male patients that received vitamin E-fortified risperidone and those receiving risperidone treatments alone.
METHODS: This study was a pre- and post-test experimental design which compared two groups; a group of men with schizophrenia who were given risperidone treatment with added Vitamin E and another group of men with schizophrenia who were given only risperidone treatment. The study was conducted at the outpatient clinic of Prof.dr. M. Ildrem Mental Hospital Medan, North Sumatra within August to November 2019. The study has been approved by the Research Ethics Committee of the Faculty of Medicine, North Sumatera University. The instrument used to assess negative scale on the subjects is PANSS.
RESULTS: We found that statistical analysis using corrected Mann–Whitney U-test obtained p < 0.001 (p < 0.05).
CONCLUSIONS: There was a strongly significant difference in negative scale Positive and Negative Syndrome Scale (PANSS) scores on 4th and 8th weeks in the group which received risperidone treatment with additional Vitamin E compared to the other group that received risperidone alone.Downloads
Metrics
Plum Analytics Artifact Widget Block
References
Arroll MA, Wilder L, Neil J. Nutritional interventions for the adjunctive treatment of schizophrenia: A brief review. Nutr J. 2014;13:91. https://doi.org/10.1186/1475-2891-13-91 PMid:25228271 DOI: https://doi.org/10.1186/1475-2891-13-91
Sadock BJ, Sadock VA. Schizophrenia Spectrum and Other Psychotic Disorders. In: Kaplan and Sadock’s Synopsis of Psychiatry Behavioral Sciences, Clinical Psychiatry. 11th ed. Philadelphia, PA: Lippincott Willias & Wilkins; 2015. p. 301. https://doi.org/10.1097/00004850-198907000-00008 DOI: https://doi.org/10.1097/00004850-198907000-00008
Brown HE, Roffman JL. Vitamin supplementation in the treatment of schizophenia. CNS Drugs. 2014;28(7):611-22. https://doi.org/10.1007/s40263-014-0172-4 PMid:24846474 DOI: https://doi.org/10.1007/s40263-014-0172-4
Buskovic M, Vovk T. Can supplementation with Vitamin E or C and omega-3 or 6 fatty acids improve the outcome schizophrenia? Rev Sci Artiles. 2008;59:167-73.
Gunes M, Altindag A, Bulut M, Demir S, Ibiloglu AO, Kaya MC, et al. Oxidative metabolism may be associated with negative symptoms in schizophrenia. Psychiatry Clin Psychopharmacol. 2017;27:54-61. https://doi.org/10.1080/24750573.2017.1293243 DOI: https://doi.org/10.1080/24750573.2017.1293243
Yao JK, Keshavan MS. Antioxidant, Redox Signaling, and Pathophysiology in Schizophrenia: An integrative View. New York: Mary Ann Liebert Inc.; 2011. p. 2011-35.
Pandya CD, Howell KR, Pillai A. Antioxidants as potential therapeutics for neuropsychiatric disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2013;46:214-23. PMid:23123357
Combs GF, McClung JP. Vitamin E. In: The Vitamins Fundamental Aspects in Nutrition and Health. 5th ed. Amsterdam: Elsevier Inc.; 2017. p. 207-42.
Aggarwal BB, Sundaram C, Prasad S, Kannappan R. Tocotrienols, the Vitamin E of the 21st Century: Its potential against cancer and other chronic diseases. Biochem Pharmacol. 2011;80(11):1613-31. https://doi.org/10.1016/j.bcp.2010.07.043 PMid:20696139 DOI: https://doi.org/10.1016/j.bcp.2010.07.043
Ghodake SR, Suryakar AN, Padalkar RK, Shaikh K. The effect of combined Vitamine E and C supplementation on the oxidative stress parameters in patients with schizophrenia. Biochem Indian J. 2012;6:155-61.
Lin CH, Lane HY. Early identification and intervention of schizophrenia: Insight from hypotheses of glutamate dysfunction and oxidative stress. Fourt Psychiatry. 2019;10:93. https://doi.org/10.3389/fpsyt.2019.00093 PMid:30873052 DOI: https://doi.org/10.3389/fpsyt.2019.00093
Doi N, Hoshi Y, Itokawa M, Yoshikawa T, Ichikawa T, Arai M, et al. Paradox of schizophrenia genetics: Is a paradigm shift occuring? Behav Brain Funct. 2012;8:1-18. https://doi.org/10.1186/1744-9081-8-28 DOI: https://doi.org/10.1186/1744-9081-8-28
Downloads
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2021 Risni Nanda, Elmeida Effendy, Mustafa Mahmud Amin (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
http://creativecommons.org/licenses/by-nc/4.0
